Biotech · Private company · Fort Wayne, IN, US
Vivacelle Bio
Track this companyFree. Adds Vivacelle Bio to your Dealase workspace and tells you when its record changes.
Clinical trials20 recruiting or active
Pipeline programs1From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline1
- VBI-SPhase 3 · Septic ShockClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials2
- A Phase III, Open Label, Randomized, Controlled Study of VBI-S in the Treatment of Hypovolemia in Patients With Septic Shock (VBI-S-02)PHASE3 · COMPLETED · started Aug 6, 2024ClinicalTrials.gov NCT06072430 · fetched Nov 12, 2026
- VBI-S for the Treatment of Hypotension in Hypovolemic Septic Shock PatientsPHASE2 · UNKNOWN · started Feb 17, 2020ClinicalTrials.gov NCT04257136 · fetched Nov 12, 2026
NIH awards3
- Development of a Phospholipid Nanoparticle-based Volume Expander for Blood Volume Replacement and Organ Protection in Hemorrhagic ShockFiscal year 2026 · $313.9KNIH RePORTER 1R43HL186835-01 · fetched Nov 12, 2026
- Development of a phospholipid nanoparticle and small molecule-based combination drug for the treatment of lethal sepsisFiscal year 2026 · $690.9KNIH RePORTER 1R44GM165137-01 · fetched Nov 12, 2026
- Development of VBI-1 as a novel treatment protocol for outpatient cardiac arrestFiscal year 2024 · $279.6KNIH RePORTER 1R41HL174360-01 · fetched Nov 12, 2026